Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1463 of 6351
-
Can a new gel outsmart stubborn acne?
Disease control CompletedDouble blinded, randomized, placebo-controlled trial to determine the safety and efficacy of topical AT-004 therapy in participants with acne vulgaris, including assessment of reduction in the number of acne lesions and IGA. A PK sub-study will be performed in a subset of partici…
Phase 2 • Sponsor: Arctic Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New pill combo aims to ease stubborn shingles nerve pain
Symptom relief Recruiting nowThe goal of this clinical trial is to assess the efficacy and safety of Y-4 in patients with postherpetic neuralgia(PHN). The main questions it aims to answer are: The efficacy and safety of Y-4 to treat PHN compared with pregabalin. Researchers will analyze data from different…
Phase 2 • Sponsor: Neurodawn Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo aims to soothe Alzheimer's agitation
Symptom relief Recruiting nowThe goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Phase 2/3 • Sponsor: Exciva GmbH • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Quantum-Powered vaccine takes on endometrial cancer
Vaccine By invitation onlyGYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma. All participants receive GYNORYLAQ-TM, a personalized neoantigenic peptide vaccine generated by the GYNORYLAQ-EC™…
Early phase 1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
AI-Designed cancer vaccine enters human testing for colorectal cancer
Vaccine Recruiting nowThis is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide vaccine, administered in combination with standard adjuvan…
Early phase 1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
New radiation boost aims to zap prostate tumors harder, faster
Disease control Recruiting nowThis study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two emerging radiation treatment techniques (hypofractionate…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Patient stories could unlock new treatments for rare appendix cancer
Knowledge-focused Recruiting nowACPMP's first-ever patient-powered global patient registry/natural history study collects patient and caregiver information and data to fuel clinical trials and drive breakthroughs for appendix cancer and PMP. We've invested the time and resources to make our Registry regulatory …
Sponsor: Appendix Cancer Pseudomyxoma Peritonei Research Foundation • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can training be timed to a Woman's cycle? a new study investigates
Knowledge-focused CompletedThis study aims to investigate the biochemical, hormonal, and physiological adaptations to a 10-week periodized high-intensity interval training (HIIT) programme in elite female futsal players. The study will examine changes in aerobic fitness, blood lactate kinetics, muscle dama…
Sponsor: Soran University • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
New hope for teens with painful skin condition: experimental drug povorcitinib under study
Disease control Recruiting nowThe purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill for chronic hives tested in thousands of patients
Disease control Recruiting nowProspective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New injection shows promise for kidney disease patients
Disease control Not yet recruitingThis is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
Phase 2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug aims to get sepsis patients off ventilators faster
Disease control Recruiting nowThe goal of this clinical trial is to learn if YD0743 works to treat sepsis-associated acute respiratory distress syndrome (ARDS) in adult patients admitted to the Intensive Care Unit. It will also learn about the safety of drug YD0743. The main questions it aims to answer are: …
Phase 2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for advanced lung cancer patients with no options left
Disease control Recruiting nowThe present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint in…
Sponsor: Karl Landsteiner University of Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New peptide injection could get athletes back in the game faster
Disease control Recruiting nowThis randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 15…
Phase 2 • Sponsor: Hudson Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a mitochondrial peptide help reverse prediabetes?
Disease control Recruiting nowThis Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity. Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle coun…
Phase 2 • Sponsor: Hudson Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Texts and apps could help at-risk youth seek psychosis care earlier
Knowledge-focused Recruiting nowThis proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis. Leveraging the Health Action Process Approach (HAPA) model, this study will…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can we predict endometriosis recurrence and fertility outcomes?
Knowledge-focused Recruiting nowEndometriosis is a chronic condition that may cause pelvic pain, ovarian cysts, infertility, and recurrent symptoms. This prospective observational cohort study will enroll women aged 18 to 45 years with endometriosis and age- and body mass index-matched healthy women. Participan…
Sponsor: Li Li • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a blood filter save lives in septic shock?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate if a blood purification treatment called "Oxiris" works to help adults with septic shock. The main questions it aims to answer are: (1) Does Oxiris treatment lower the risk of death or organ failure within the first 7 days? (2) Does …
Sponsor: Pusan National University Yangsan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Beats over blood pressure: music campaign aims to prevent stroke in nigeria
Prevention OngoingExpanding evidence-based interventions for hypertension and stroke prevention among youth and their caregivers is crucial for meeting World Health Organization and Nigerian health goals. Innovative strategies are urgently needed to address the burden of hypertension and stroke in…
Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
Disease control CancelledThis study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Nephropathy (IgAN), a common kidney disease that can lead to kidney failure. The AIP diet avoids foods that may cause infla…
Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC